Ifupinostat
Previously Untreated Peripheral T-Cell Lymphoma
BeBetter Med IncSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Previously Untreated Peripheral T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifupinostat Hydrochloride For BeBetter Med Inc | Phase 2 | CCC |
PREDNISONE TABLETS BeBetter Med Inc | Phase 2 | CCC |
Same molecule, other indications
Ifupinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →